Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Daiichi Sankyo Inks Discovery Deal With Next-Gen Protein Player Pieris

This article was originally published in PharmAsia News

Executive Summary

Privately-held Pieris AG announced April 12 a two-target partnership with Tokyo-based Daiichi Sankyo Co. Ltd. It is the German firm's latest alliance to center upon its proprietary anticalin platform and demonstrate its broad utility, which will be necessary if an acquisition is to transpire, although the company says it's not looking for an exit right now

Latest Headlines
See All
UsernamePublicRestriction

Register

SC077644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel